Normal view MARC view ISBD view

Wu, Xiao Yu

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. [electronic resource] - Oncotarget Dec 2015 - 44563-78 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

ISSN: 1949-2553

Standard No.: 10.18632/oncotarget.6310 doi

Subjects--Topical Terms:
Angiogenesis Inhibitors--pharmacology
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Aorta--drug effects
Breast Neoplasms--blood supply
Cell Proliferation--drug effects
Chick Embryo
Chorioallantoic Membrane--blood supply
Dose-Response Relationship, Drug
Female
Human Umbilical Vein Endothelial Cells--drug effects
Humans
Indoles--pharmacology
Isoflavones--pharmacology
MCF-7 Cells
Male
Mice, Inbred BALB C
Mice, Nude
Neovascularization, Pathologic
Neovascularization, Physiologic--drug effects
Phosphorylation
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins c-akt--metabolism
Pyrroles--pharmacology
Rats, Sprague-Dawley
Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors
STAT3 Transcription Factor--metabolism
Signal Transduction--drug effects
Sunitinib
Time Factors
Tumor Burden--drug effects
Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors
Xenograft Model Antitumor Assays